Walethmade%252525252525252525252525252525252525252525252525252525252525252525252525252520bromide

# Walethmade bromide (Glycopyrrolate) ## Overview Glycopyrrolate (often referred to as glycopyrronium bromide) is a synthetic quaternary ammonium anticholinergic agent. Unlike atropine, it does not cross the blood-brain barrier effectively, resulting in fewer central nervous system side effects. ## Primary Indications * Reduction of secretions (preoperative or chronic severe drooling in neurologic conditions). * Reversal of muscarinic effects of anticholinesterase agents (e.g., neostigmine). * Treatment of peptic ulcer disease (adjunctive therapy; less common). * Control of upper airway secretions in palliative care. ## Adult Dosing * **Preoperative Anticholinergic:** 0.1–0.2 mg IM or IV; usually administered 30–60 minutes prior to surgery. * **Reversal of Neuromuscular Blockade:** 0.2 mg for every 1 mg of neostigmine administered. * **Chronic Sialorrhea:** 1–2 mg orally 3 times daily (titrate to clinical effect). * **Peptic Ulcer:** 1 mg PO twice daily or 0.1–0.2 mg IM/IV every 4–6 hours. ## Pediatric Dosing * **Intraoperative/Anesthesia:** 0.004–0.01 mg/kg IV/IM (max 0.2 mg). * **Chronic Sialorrhea:** 0.02–0.1 mg/kg PO TID (starting dose typically 0.02 mg/kg); monitor closely for side effects. * *Note: Pediatric dosing depends heavily on weight and local clinical protocol; always verify institutional guidelines.* ## Dose Adjustments * **Renal Impairment:** Reduce frequency or avoid. Glycopyrrolate is primarily renally eliminated. Accumulation occurs in patients with CrCl < 30 mL/min. * **Hepatic Impairment:** No specific guidelines; use with caution. ## Contraindications * Hypersensitivity to the drug. * Glaucoma (narrow-angle). * Obstructive uropathy (e.g., prostatic hypertrophy). * Severe ulcerative colitis or megacolon. * Myasthenia gravis (unless used for neostigmine reversal). * Tachycardia secondary to cardiac insufficiency or thyrotoxicosis. ## Adverse Effects * **Common:** Dry mouth (xerostomia), blurred vision, mydriasis, constipation, urinary retention, and tachycardia. * **Severe:** Heat prostration (decreased sweating), allergic reactions, and confusion (less common than with tertiary anticholinergics). ## Key Drug Interactions * **Potentiation:** Increased anticholinergic effects when combined with antihistamines, tricyclic antidepressants, or phenothiazines. * **Absorption:** May decrease the absorption of other oral medications by slowing GI motility. * **Potassium Chloride:** Solid oral formulations of KCl may cause intensified GI lesions if co-administered with anticholinergics. ## Monitoring * Heart rate (monitor for excessive tachycardia). * Intake and output (monitor for urinary retention). * Bowel function (monitor for constipation/ileus). * Changes in mental status (especially in elderly patients). ## Clinical Pearls * Quaternary structure limits CNS penetration, making glycopyrrolate less likely to cause cognitive impairment compared to scopolamine or atropine. * When used for chronic drooling, emphasize oral hygiene as the resulting xerostomia increases the risk of dental caries. * Always distinguish between the injectable solution and the oral tablet formulations; dosing is not interchangeable. *** **Educational Disclaimer:** This information is for educational purposes only. Drug dosing, indications, and safety profiles are subject to change based on evolving clinical data and local institutional protocols. Always consult current, full prescribing information (such as the FDA label) and your facility’s clinical pharmacists or medical guidelines before prescribing or administering medication.